Ambry Genetics Leading the Way With Clinical Next-Generation Sequencing


Ambry Genetics
15 Argonaut
Aliso Viejo, CA 92656

In early March, Ambry Genetics (Aliso Viejo, Calif.) reached the milestone of having
sequenced 10,000 clinical diagnostic samples with next-generation sequencing (NGS)
and processed 100,000 total NGS samples. Ambry has a proud history of being on the
forefront of genetic testing, having been among the first purchasers of commercially
available sequencing instruments back in 2007. The company says it was the first to offer
an NGS-based diagnostic test in April 2010, with the introduction of its 81-gene panel
for X-linked intellectual disability. Ambry continued with its list of firsts by launching
the first clinically available whole-exome sequencing test at a CLIA-certified laboratory
in 2011.

Evolving from its roots in cystic fibrosis (CF) testing, Ambry continues to develop and
enhance its comprehensive testing menu with significant investments in automation.
This has allowed the company to focus on reducing test turnaround time while retaining
its focus on quality client service and steadfast attention to their guiding ethical
principles. Recently, Ambry CEO Charles Dunlop spoke to DTTR about the evolution of NGS in
clinical care and Ambry’s commitment to rapid, yet responsible, growth in the future.

Read Full Article Here

About Ambry Genetics ®

Ambry Genetics is both College of American Pathologists (CAP)-accredited and Clinical Laboratory Improvement Amendments (CLIA)-certified. Ambry leads in clinical genetic diagnostics and genetics software solutions, combining both to offer the most comprehensive testing menu in the industry. Ambry has established a reputation for sharing data while safeguarding patient privacy, unparalleled service, and responsibly applying new technologies to the clinical molecular diagnostics market. For more information about Ambry Genetics, visit

Press Contact:
Aaron Schmidt
Sr Manager, Communications
949 457 4679

Search Results

Start your search...